Hansa Biopharma AB - Company Profile

Powered by

All the data and insights you need on Hansa Biopharma AB in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Hansa Biopharma AB Strategy Report

  • Understand Hansa Biopharma AB position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Hansa Biopharma AB: Overview

Select Item

Hansa Biopharma AB (Hansa Biopharma) focuses on the development of novel immunomodulatory enzymes for transplantation, gene therapy, cancer and acute autoimmune diseases. The company's lead project, imlifidase is a proprietary antibody cleaving enzyme for kidney transplant patients which is protected by 6 patent families. Its preclinical assets include NiceR for recurring treatment in autoimmune disease, transplantation, and cancer; and EnzE, cancer immunotherapy. Hansa Biopharma offers a novel diagnostic method HBP-assay (serum quantification of Heparin Binding Protein) to help predict severe sepsis in patients with infectious disease symptoms. The company has out-licensed its HBP-assay (serum quantification of Heparin-Binding Protein), a novel diagnostic method to help predict severe sepsis in patients with infectious disease symptoms to Axis-Shield Diagnostics. It has its operations in Other European Countries and the US. Hansa Biopharma is headquartered in Lund, Sweden.

 Gain a 360-degree view of Hansa Biopharma AB and make more informed decisions for your business Gain a 360-degree view of Hansa Biopharma AB and make more informed decisions for your business Find out more
Headquarters Sweden
Address P.O. Box 785, Scheelevagen 22, Lund, 22007
Website www.hansabiopharma.com
Telephone 46 46 165670
No of Employees 168
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange HNSA (STO)
Revenue (2022) $12.6M -13.2% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ -36.1% (2022 vs 2021)
Market Cap* $147.3M
Net Profit Margin (2022) XYZ -56.8% (2022 vs 2021)
* As of and is in US$
View Hansa Biopharma AB financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Hansa Biopharma AB premium industry data and analytics

50+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Hansa Biopharma AB’s relevant decision makers and contact details.

30+

Catalyst Calendar

Proactively evaluate Hansa Biopharma AB’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

20+

Clinical Trials

Determine Hansa Biopharma AB go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

6

Pipeline Drugs

Identify which of Hansa Biopharma AB’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

3

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

1

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Marketed Drugs

Understand Hansa Biopharma AB’s commercialized product portfolio to stay one step ahead of the market.

Products and Services

Products
Pipeline Drugs:-
Imlifidase:
Kidney Transplantation
XYZ
XYZ
XYZ
Understand Hansa Biopharma AB portfolio and identify potential areas for collaboration Understand Hansa Biopharma AB portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Contracts/Agreements In April, the company announced collaboration agreement with Genethon to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies.
2022 Contracts/Agreements In January, the company entered into an agreement with AskBio to evaluate the potential use of imlifidase as a pre-treatment prior to the administration of gene therapy in Pompe disease .
2021 Contracts/Agreements In March, the company entered into a research collaboration with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Hansa Biopharma AB Swedish Orphan Biovitrum AB Calliditas Therapeutics AB BioInvent International AB Diamyd Medical AB
Headquarters Sweden Sweden Sweden Sweden Sweden
City Lund Solna Stockholm Lund Stockholm
State/Province - - Stockholm - -
No. of Employees 168 1,772 181 111 26
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Peter Nicklin Chairman Executive Board 2022 60
Soren Tulstrup President; Chief Executive Officer Senior Management 2018 58
Evan Ballantyne Chief Financial Officer Senior Management 2024 -
Achim Kaufhold Chief Medical Officer; Senior Vice President Senior Management 2020 66
Hitto Kaufmann Ph.D Chief Scientific Officer Senior Management 2023 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Hansa Biopharma AB key executives to enhance your sales strategy Gain insight into Hansa Biopharma AB key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward